Drug Development Programme — UK

The Sarah Cannon Research Institute—UK Drug Development Programme offers consistent performance and excellence through a dedicated, experienced oncology drug development team, state-of-the-art clinical trials unit in central London, competitive start-up timelines, and rapid patient accrual within a large referral network.

Our Facility
- CQC-registered oncology trials unit
- On-site pharmacy
- PK testing facilities
- -20 + -80° C freezers
- Refrigerated and non-refrigerated centrifuges
- Cardiac monitoring
- Access to hospital-based critical care services
- 12 treatment chairs/beds
- Molecular profiling capabilities

For Patients
- Broad clinical trials portfolio (solid and hematological malignancies)
- Patient-centered support services and referrals
- Private areas for treatment
- On-site catering for patients
- Wireless internet and individual patient entertainment systems

For Partners
We are committed to our partners’ goals, and we tailor our teams and processes to meet them, ensuring strong science and consistent quality every step of the way. As collaborators, we strive to provide superior insights that contribute to discovery and success.

Our Team of Professionals
We have a fully-staffed nursing and clinical research team including:
- Principal investigators
- Clinical research fellows
- Clinical trial management team
- Quality assurance manager
- Pharmacy team
- Administrative office support
- Laboratory team
- Data entry team

Facility Amenities and History
- 13,000 square feet purpose-designed facility
- Registered listed historic building on Harley Street
- Central London location serviced by three main rail stations and Tube

Study Metrics
- More than 70 clinical trials initiated across all study phases and tumor types
- Pre-screened more than 900 patients for rare mutations, amplifications or other alterations
- 112 patients enrolled in 2014

sarahcannonresearch.co.uk
United Kingdom Leadership

We have a fully-staffed nursing and clinical research team, including principal investigators, clinic and research nurses, clinical trial managers, data coordinators, regulatory affairs specialists, pharmacy technicians, and day and evening pharmacokinetic technicians.

Hendrik-Tobias Arkenau, MD, PhD, FRCP
Executive Medical Director, Drug Development Program,
Sarah Cannon Research Institute - UK

Arkenau has vast experience in early oncology clinical drug development with a special interest in gastrointestinal cancer and melanoma. He received his medical degree in 2000 at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. Before joining Sarah Cannon Research Institute-UK, he was senior clinical fellow at the Royal Marsden Hospital and team leader for early drug development at the Prince of Wales Clinical School at the University of New South Wales, Sydney, Australia.

Contact Information:
(E) tobias.arkenau@sarahcannonresearch.co.uk

Matthew Simmons
Head of Drug Development Unit,
Sarah Cannon Research Institute - UK

Simmons has extensive operational and commercial experience across all phases of drug development within the pharmaceutical and CRO industries. He has overall responsibility for the day-to-day management of the Sarah Cannon Research Institute-UK Drug Development Unit. Simmons received his degree in molecular biology from The University of Manchester in 1994, and joined what was then SmithKline Beecham, working on the clinical development of a novel cytotoxic agent. Immediately before joining Sarah Cannon Research Institute-UK, he managed the global commercial operations teams for Worldwide Clinical Trials, a mid-sized, full-service CRO.

Contact Information:
(E) matthew.simmons@sarahcannonresearch.co.uk

Saeed Rafii, MD, PhD, MRCP
Medical Director, Drug Development,
Sarah Cannon Research Institute - UK

Rafii is a consultant medical oncologist with an interest in early phase experimental cancer medicine. He completed his PhD in the molecular genetics of DNA repair in breast cancer and completed his medical oncology training in Birmingham and The Royal Marsden Hospital followed by a Fellowship in early phase drug development at The Institute of Cancer Research at The Royal Marsden. Before joining SCRI-UK, he was Clinical Senior Lecturer and Consultant Medical Oncologist at The Christie Hospital in Manchester. As well as early phase clinical trials, Rafii has a particular interest in gynecological malignancies.

Contact Information:
(E) saeed.rafii@sarahcannonresearch.co.uk

Above all else, we are committed to the improvement of patient outcomes and advancement of medical science through innovation and quality execution of cancer research.

sarahcannonresearch.co.uk